Shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) were down 4.7% during trading on Thursday . The stock traded as low as $4.83 and last traded at $4.84. 136,263 shares traded hands during trading, a decline of 48% from the average session volume of 261,100 shares. The stock had previously closed at $5.08.
Aadi Bioscience Trading Down 4.7%
The business’s 50 day simple moving average is $4.25 and its 200 day simple moving average is $3.95. The firm has a market capitalization of $119.53 million, a PE ratio of -2.12 and a beta of 0.68.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Further Reading
- Five stocks we like better than Aadi Bioscience
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
